NCT01906125 - A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Healthy

Interventions

DRUG

palbociclib capsule: phase 1 and 2 studies

125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies

DRUG

Palbociclib capsule: phase 3 studies

125 mg dose of palbociclib. Formulation used in phase 3 studies

DRUG

Palbociclib capsule: ICH

125 mg dose of palbociclib. Intended final market formulation

Trial Locations (1)

Pfizer Investigational Site, Overland Park